Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

522 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Small-cell lung cancer: what we know, what we need to know and the path forward.
Gazdar AF, Bunn PA, Minna JD. Gazdar AF, et al. Nat Rev Cancer. 2017 Nov 10;17(12):765. doi: 10.1038/nrc.2017.106. Online ahead of print. Nat Rev Cancer. 2017. PMID: 29123245
Small-cell lung cancer: what we know, what we need to know and the path forward.
Gazdar AF, Bunn PA, Minna JD. Gazdar AF, et al. Nat Rev Cancer. 2017 Dec;17(12):725-737. doi: 10.1038/nrc.2017.87. Epub 2017 Oct 27. Nat Rev Cancer. 2017. PMID: 29077690 Review.
Long-term safety and survival with gefitinib in select patients with advanced non-small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP).
Hirsch FR, Sequist LV, Gore I, Mooradian M, Simon G, Croft EF, DeVincenzo D, Munley J, Stein D, Freivogel K, Sifakis F, Bunn PA Jr. Hirsch FR, et al. Cancer. 2018 Jun 1;124(11):2407-2414. doi: 10.1002/cncr.31313. Epub 2018 Mar 26. Cancer. 2018. PMID: 29579334
Abdominal computed tomography in small cell lung cancer: assessment of extent of disease and response to therapy.
Ihde DC, Dunnick NR, Johnston-Early A, Bunn PA, Cohen MH, Minna JD. Ihde DC, et al. Cancer. 1982 Apr 1;49(7):1485-90. doi: 10.1002/1097-0142(19820401)49:7<1485::aid-cncr2820490729>3.0.co;2-l. Cancer. 1982. PMID: 6277467
Therapy for multiple myeloma with alternating non-cross-resistant chemotherapy combinations: heterogeneity of tumor responsiveness.
Morstyn G, Schechter GP, Ihde DC, Carney DN, Eddy JL, Cohen MH, Minna JD, Bunn PA Jr. Morstyn G, et al. Cancer Treat Rep. 1984 Dec;68(12):1439-46. Cancer Treat Rep. 1984. PMID: 6391662 Clinical Trial.
Letter: Should ineffective agents be used in combination chemotherapy?
Bunn PA Jr. Bunn PA Jr. Cancer Chemother Rep. 1974 Mar-Apr;58(2):127-8. Cancer Chemother Rep. 1974. PMID: 4830494 No abstract available.
The clinical behavior of "mixed" small cell/large cell bronchogenic carcinoma compared to "pure" small cell subtypes.
Radice PA, Matthews MJ, Ihde DC, Gazdar AF, Carney DN, Bunn PA, Cohen MH, Fossieck BE, Makuch RW, Minna JD. Radice PA, et al. Cancer. 1982 Dec 15;50(12):2894-902. doi: 10.1002/1097-0142(19821215)50:12<2894::aid-cncr2820501232>3.0.co;2-g. Cancer. 1982. PMID: 6291745
Growth rates of small cell bronchogenic carcinomas.
Brigham BA, Bunn PA Jr, Minna JD, Cohen MH, Ihde DC, Shackney SE. Brigham BA, et al. Cancer. 1978 Dec;42(6):2880-6. doi: 10.1002/1097-0142(197812)42:6<2880::aid-cncr2820420650>3.0.co;2-x. Cancer. 1978. PMID: 215299
A Southwest Oncology Group Phase I study of the sequential combination of recombinant interferon-gamma and recombinant interleukin-2 in patients with cancer.
Taylor CW, Chase EM, Whitehead RP, Rinehart JJ, Neidhart JA, Gonzalez R, Bunn PA, Hersh EM. Taylor CW, et al. J Immunother (1991). 1992 Apr;11(3):176-83. doi: 10.1097/00002371-199204000-00004. J Immunother (1991). 1992. PMID: 1515422 Clinical Trial.
522 results
Jump to page
Feedback